Fundz

Sv Health Investors Joins Prilenia Series B As The Company Prepares For Als And Hd Data Readouts In The Next 12 Months

PRIVATEApr 12, 2022

Round Type

Series B

BostonBiotechnologyHealth CareTherapeutics

Description

Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, today announced that it has raised an additional $10 million, bolstering the Series B financing round and bringing total capital raised to date to $144 million.

Quick answer

Prilenia raised an undisclosed amount in a Series B round, dated April 12, 2022. Prilenia is based in Boston, Massachusetts, United States.

How much did Prilenia raise?
Prilenia raised an undisclosed amount in a Series B round on April 12, 2022.
What does Prilenia do?
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders.
Where is Prilenia based and how big is it?
Prilenia is based in Boston, Massachusetts, United States. Fundz records about 60 employees.
Who are the decision-makers at Prilenia?
Fundz holds 1 contact at Prilenia. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Prilenia that raised within 45 days of this round, from Fundz verified event records.

  • Biofrontera raised $9.4M on May 23, 2022.
  • Tempest Therapeutics raised $15M on May 11, 2022.
  • MitoRx Therapeutics raised an undisclosed amount (Seed) on April 25, 2022.
  • CytoDyn raised $1.9M (Seed) on April 22, 2022.
  • BioNTech raised $150M on April 14, 2022.
  • KayoThera, Inc. raised $10M (Series A) on March 24, 2022.

Who to call at Prilenia, and when

A new round usually means Prilenia is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Prilenia raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Prilenia, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Prilenia. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Prilenia

Location

Boston, Massachusetts, United States

About

Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Prilenia raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Prilenia's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Prilenia raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.